What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.

The fortunes of RLY-2608 reverse, and a pivotal study will follow.

The new developer will focus on the crowded KRAS space and PI3Kα/AKT inhibition, which has been hit by toxicity issues.

With inavolisib’s pivotal front-line win Roche reckons it can knock out Novartis’s Piqray.